Ask about FDA oncology approvals, clinical trials, and treatment guidelines. Launch Oncology AI Chat Introduction Zongertinib (BI 1810631) has shown promising results in treating HER2-mutant non-small cell lung cancer (NSCLC), with a 71% response rate as presented at AACR 2025. This oral, HER2-selective tyrosine kinase inhibitor (TKI) offers a new option for patients with this … Continue reading Zongertinib 71% ORR for HER2-Mutant NSCLC: Key Insights from AACR 2025